LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial
J Mark FitzGerald (Vancouver, Canada), J. Mark FitzGerald, Eugene Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Gary Ferguson, William Busse, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Viktoria Werkström, Magnus Aurivillius, Mitchell Goldman
|    |
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
Katharine Abbott-Banner (London, United Kingdom), Dave Singh, Katharine Abbott-Banner, Kenneth Newman
| |
LATE-BREAKING ABSTRACT: Exploiting the ability of 1H-NMR to differentiate patients with severe alpha-1-antitrypsin deficiency from controls based on metabolome profiling of exhaled breath condensate
Jan Stolk (Leiden, Netherlands), M. Fumagalli, Jan Stolk, C. Ciaramelli, R. Bussei, V. Mazzoni, S. Viglio, Paolo Iadarola, C. Airoldi
| |
LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients
Jørgen Vestbo (Manchester, United Kingdom), Jorgen Vestbo, Massimo Corradi, Isabella Montagna, Géraldine Cohuet, Catherine Francisco, Stefano Vezzoli, Annamaria Muraro, Stefano Petruzzelli, Mario Scuri, Dave Singh
| |
LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD
Peter M. A. Calverley (Liverpool, United Kingdom), Peter M.A. Calverley, Kay Tetzlaff, Claus Vogelmeier, Leonardo M. Fabbri, Helgo Magnussen, Emiel F.M. Wouters, Bernd Disse, Helen Finnigan, Guus M. Asijee, Henrik Watz
| |
LATE-BREAKING ABSTRACT: The PDE4 inhibitor CHF-6001 and LAMAs cooperatively inhibit bronchoconstriction-induced remodeling in lung slices
Loes Kistemaker (Groningen, Netherlands), Loes E.M. Kistemaker, Tjitske A. Oenema, Wim A. de Jager, I. Sophie T. Bos, Fabrizio Facchinetti, Gino Villetti, Reinoud Gosens
| |
LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma
Nicola Hanania (Houston, United States of America), Nicola Hanania, Phillip Korenblat, Kenneth R. Chapman, Eric D. Bateman, Petr Kopecky, Pier L. Paggiaro, Akihito Yokoyama, Julie Olsson, Sarah Gray, Cecile T.J. Holweg, Mark Eisner, Charles Asare, John G. Matthews
| |
LATE-BREAKING ABSTRACT: Tackling the burden of chronic cough: A dose escalation study of AF-219
Jaclyn Smith (Manchester, United Kingdom), Jaclyn Smith, Michael Kitt, Mandel Sher, Peter Butera, Anthony Ford
| |